查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103297

人源化小鼠與大鼠模型市場：全球市場預測，2026-2032年

Humanized Mouse & Rat Model Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人源化小鼠和大鼠模型市場將成長至 4.9448 億美元，複合年成長率為 7.54%。

主要市場統計數據
基準年 2025 2.9724億美元
預計年份：2026年 3.1757億美元
預測年份：2032年 4.9448億美元
複合年成長率 (%) 7.54%

人源化小鼠和大鼠模型市場概覽

人源化小鼠和大鼠模型在轉化研究中日益重要，因為它們能夠在受控的臨床前環境中對人類免疫反應、疾病生物學機制、治療機制和安全性訊號進行體內研究。這些模型在腫瘤學、免疫力缺乏、傳染病、自體免疫免疫疾病、再生醫學、藥物感染疾病和藥物動力學研究中非常有用，因為它們是透過將人類細胞、組織、基因、微生物組成分或人類特異性基因序列導入免疫缺陷或基因修飾的囓齒動物而建構的。推動這些模型應用的因素包括：提高向臨床應用的轉化效率、減少後期研究中斷以及在人體臨床試驗前獲得預測性證據。 CRISPR和其他基因組編輯技術、幹細胞生物學、造血幹細胞異質骨移植、人類細胞激素敲入系統以及人類免疫系統重建等方面的進展也促進了這些模型在科學界的應用。同時，出於對動物使用的倫理考量，研究人員正轉向設計更合理、更有價值的研究，以符合「3R」原則（替代、減少、改進）。因此，人源化小鼠和大鼠模型的模式正在從專門的研究工具演變為精準醫療、生技藥品開發、疫苗評估、腫瘤免疫藥物發現以及與人類相關的臨床前檢驗的戰略平台。

人源化小鼠和大鼠模型的變革性變化

人源化小鼠和大鼠模型的模式正在經歷一場結構性轉變，從傳統的異種移植和基因敲入系統轉向高度客製化、應用特異性的平台，這些平台能夠更真實地模擬人類的生理功能。 CRISPR基因編輯技術正在加速建構具有標靶免疫查核點通道、細胞激素網路、人類白血球抗原（HLA）表現、Fc受體生物學特性以及疾病特異性遺傳背景的模型。免疫腫瘤學是這項轉變的主要驅動力，研究人員利用人源化小鼠模型來評估查核點抑制劑、雙特異性抗體、抗體藥物偶聯物（ADC）、細胞療法、腫瘤浸潤淋巴細胞動力學以及與腫瘤微環境的相互作用。在感染疾病研究中，人源化模型在病毒致病性和疫苗反應研究中的應用也在不斷增加，尤其是在物種特異性宿主因素限制了傳統動物實驗的情況下。另一項突破性變革是擴大使用患者來源的材料，例如腫瘤組織、免疫細胞、類器官和幹細胞，以支持個人化療法的篩檢和機制研究。由於大鼠模型在體型、可重複取樣、行為評估、縱向藥理學研究和手術可行性等方面優於小鼠，因此日益受到關注。同時，隨著監管機構和部門要求的不斷提高，模型檢驗、可重複性、透明報告、標準化終點和嚴格的動物福利監管也日益受到重視，使得品質、可追溯性和研究設計成為越來越重要的差異化因素。

人工智慧對人性化模型的累積影響

人工智慧 (AI) 透過改進模型設計、隊列選擇、影像分析、生物標記解讀和轉換預測，正在拓展人源化小鼠和大鼠模型的價值。 AI 驅動的文獻挖掘和體學數據整合使研究人員能夠在研發開始前識別相關的人類基因、免疫通道、疾病特徵、生物標記候選物和模型選擇標準。機器學習正被應用於組織病理學、流式細胞技術、單細胞測序、空間生物學、非侵入性成像和縱向行為數據，有助於檢測人工分析中可能被忽略的複雜模式。在藥物研發領域，AI 可以將臨床前數據與人類臨床數據、分子數據和真實世界生物資料集整合，以輔助劑量選擇、毒性訊號優先排序、反應分層和跨物種外推。這在免疫腫瘤學、發炎性疾病、感染疾病和先進療法中尤其重要，因為這些領域的治療反應依賴於免疫細胞之間的動態相互作用。此外，人工智慧可以透過最佳化終點指標、預測性監測、異常檢測和提高統計功效設計，幫助提高證據質量，同時保障動物福利和提升實驗效率，減少不必要的動物使用。然而，其累積影響取決於檢驗的資料集、標準化的元資料、透明的演算法、生物學可解釋性以及負責任的管治。因此，儘管人源化小鼠和大鼠模型與人工智慧正在融合，建構更具預測性的臨床前生態系統，但可重複性和嚴格的檢驗仍然是其應用推廣的關鍵。

關於人源化小鼠和大鼠模型的關鍵區域性見解

亞太地區正成為人源化小鼠和大鼠模型研究的重點區域，這得益於生物醫學領域的持續投資、不斷擴大的合約研究能力以及在腫瘤學、疫苗開發、再生醫學、感染疾病和細胞療法等領域活性化的研究活動。中國、日本、韓國、印度、澳洲和新加坡等國不斷完善的生命科學基礎設施、基因組編輯能力、生物銀行和轉化研究網路，為更多人源化免疫系統模型和患者來源的異種移植模型的應用提供了支持。北美仍然是先進臨床前研究的領先中心，這得益於其強大的學術基礎設施、成熟的生物技術生態系統、完善的動物實驗管治、聯邦政府和研究機構的大力支持，以及對免疫腫瘤學、生技藥品、感染疾病和罕見疾病模型的高需求。拉丁美洲正在穩步發展，巴西和墨西哥正在加強其生物醫學研究能力並增加對轉化研究的參與，儘管各機構的基礎設施、資金籌措持續性、生物安全系統和專業模型的可用性存在差異。在歐洲，高品質、符合倫理規範的動物研究仍是重中之重，並被廣泛應用於免疫學、腫瘤學、感染疾病、藥理學以及先進療法的研發。該地區嚴格的動物福利框架促進了檢驗、可重複且科學合理的動物模型的使用。在中東，精準醫療、基因組學、大學附屬醫療中心和生物醫學創新中心等領域的投資正在推動研究能力建設，尤其是在那些優先發展人群基因組學和轉化醫學的國家。在非洲，人源化小鼠和大鼠模型的應用仍在發展中，但具有重要的科學意義，尤其是在感染疾病、免疫學、疫苗研發以及區域疾病負擔方面。其發展取決於實驗室基礎設施、研究夥伴關係、生物安全系統、人力資源發展和永續資金籌措。

來自東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約等主要組織的真知灼見。

隨著新加坡、泰國、馬來西亞、越南、印尼和菲律賓不斷加強其在生物醫學研究、感染疾病監測、癌症研究、疫苗科學和區域臨床應用方面的能力，東協在人源化小鼠和大鼠模型生態系統中的重要性日益凸顯。儘管該地區受益於其接近性多種疾病負擔地區以及不斷擴展的實驗室網路，但成員國在專業動物模型能力、先進的免疫表現型分析和高等級生物安全設施方面仍然存在差距。海灣合作理事會（GCC）正在加大對生物醫學基礎設施、基因組學、大學醫院、生物銀行和精準醫療舉措的投資，為利用人源化模型在免疫學、代謝性疾病、腫瘤學、遺傳性疾病以及針對特定人群的治療研究等領域開展轉化研究創造了機會。歐盟透過協調研究管治、嚴格的動物福利要求、跨境研究資助以及廣泛的生物醫學創新網路發揮關鍵作用，支持在癌症、發炎、感染疾病、毒理學和先進療法等領域應用經過檢驗且符合倫理規範的人源化模型。金磚國家是一個多元化但又極具影響力的集團。中國和印度正在拓展其臨床前研究能力，巴西和南非則致力於疾病相關的生物醫學和疫苗研究，而俄羅斯則保持其在免疫學、藥理學、病毒學和實驗醫學領域的科研實力。七國集團（G7）憑藉其先進的研究機構、完善的監管體系、強大的生物技術研發管線、成熟的動物實驗標準以及在轉化藥物研發中廣泛應用人源化小鼠和大鼠模型，依然保持著極高的影響力。北約成員國與多個生物醫學已開發經濟體有重疊，這些國家在研究安全、生物安全防範、疫苗研發、感染疾病監測以及國防相關醫療反應研究等方面的考量，促使它們持續關注人源化免疫和感染疾病模型。

主要國家人源化小鼠和大鼠模型研究的趨勢

美國是全球人源化小鼠和大鼠模型研究中心，擁有許多學術實驗室、生物技術創新、免疫腫瘤學計畫、細胞和基因治療開發、感染疾病研究以及完善的臨床前研究基礎設施。加拿大憑藉其在免疫學、幹細胞、腫瘤學、疫苗和感染疾病研究方面的優勢做出貢獻，尤其注重動物倫理和轉化醫學合作。墨西哥正在拓展其生物醫學研究能力，尤其是在腫瘤學、代謝性疾病和感染疾病領域，其先進的人源化模型通常與機構間合作和專業研究網路緊密相連。巴西是拉丁美洲的主要貢獻者，在免疫學、感染疾病、癌症生物學、熱帶醫學和疫苗科學等領域擁有成熟的學術研究基礎。英國在生物醫學創新、遺傳學、免疫學和臨床前藥理學方面發揮著重要作用，這得益於其嚴格的動物福利管治和強大的轉化醫學計畫。德國以其高品質的實驗醫學、免疫學、腫瘤學、生技藥品和藥理學研究而聞名，尤其注重研究結果的可重複性和監管合規性。法國積極參與感染疾病、免疫學、腫瘤學、神經科學和疫苗研究，而義大利和西班牙則透過醫學研究、癌症生物學、神經科學、發炎性疾病研究和轉化藥理學做出貢獻。俄羅斯在實驗藥理學、病毒學、疫苗科學和免疫學方面擁有豐富的經驗，但國際合作趨勢和法規環境正在影響其獲取和整合研究成果。中國正在迅速提升其在基因組編輯、腫瘤學、感染疾病、幹細胞科學、生技藥品研究和合約研究等領域的能力，並已成為客製化人源化模型的主要用戶和開發者。印度正憑藉其不斷發展的生物技術產業和臨床研究基礎，加強在腫瘤學、感染疾病、疫苗、免疫學和生技藥品的轉化研究。日本在再生醫學、免疫學、腫瘤學、老齡化相關疾病研究和基因改造模型方面擁有強大的實力，並堅持嚴格的科學標準。澳洲透過高品質的生物醫學研究、癌症免疫學、感染疾病研究、公共衛生研究和動物倫理管治做出貢獻。韓國透過積極投資轉化醫學項目，整合生物技術、細胞療法、生物製藥、腫瘤學、精準醫療和生產製造，並依托先進的研究基礎設施，不斷提升其重要性。

為行業領導者提供的實用建議

產業領導者應優先考慮基於生物有效性、終點有效性和轉化研究適用性的模型選擇，而不是簡單地採用熟悉的平台。在免疫腫瘤學領域，人體免疫系統的組成、HLA相容性、細胞激素支持、Fc受體的生物學特性、腫瘤微環境的可重複性以及移植物抗宿主疾病（GVHD）風險應指南研究設計。在感染疾病和疫苗研究中，研究人員應評估病原體親和性、生物安全需求、免疫重建品質、攻毒模型的適用性以及具有臨床意義的保護相關性。各機構應投資於標準化表徵，包括流式細胞技術、組織病理學、細胞激素檢驗、基因組驗證、人類細胞移植評估和縱向監測，以提高研究間的可重複性。雖然人工智慧驅動的分析和多組體學整合可以增強生物標記的發現和反應預測，但應盡可能使用透明的生物學假設和獨立資料集來檢驗結果。與專業模型開發人員、學術機構、生物樣本庫和轉化研究機構建立策略夥伴關係，可以提高獲得先進模型和疾病特異性專業知識的途徑。此外，首席研究員應將3R原則（減少、最佳化、再利用）納入研究計劃，具體措施包括：運用功效分析、最佳化人道終點指標、採用非侵入性成像技術、進行縱向採樣以及採用數據共用實踐，以減少動物重複實驗。最後，決策者需要在研發早期階段，尤其是在生技藥品、細胞療法、基因療法、疫苗、抗體療法和免疫調節藥物領域，將人源化模型提供的證據與監管要求相協調。

調查方法

本執行摘要基於系統的二手研究方法，利用公開可查且可驗證的來源，包括同行評審的科學文獻、監管指南、機構動物福利框架、生物醫學研究出版物、臨床和轉化科學研究途徑以及經認可的公共衛生和研究資訊來源。分析重點在於人源化小鼠和大鼠模型發展中經科學檢驗的趨勢，包括基因組編輯、免疫系統重建、患者來源的異種移植模型、感染疾病研究、免疫腫瘤學應用、人工智慧驅動的分析、再生醫學和區域研究基礎設施。透過檢驗不同應用、地區、研究團隊和國家級創新生態系統的證據，整合了檢驗，同時避免使用未經證實的數位聲明、市場規模、市場佔有率和預測。重點在於可重複性、轉化相關性、倫理管治、生物安全考量以及人源化囓齒動物模型在臨床前決策中的適用性。此外，該調查方法考慮了免疫學、腫瘤學、藥理學、毒理學、再生醫學、疫苗科學、幹細胞生物學和計算生物學等領域的跨學科知識，從而能夠全面了解產業狀況。

結論

人源化小鼠和大鼠模型正成為彌合傳統非臨床試驗與人類臨床生物學之間鴻溝的重要工具。當標準動物模型不足以研究人類特異性免疫機制、病原體相互作用、腫瘤生物學、遺傳通道、微生物組影響或治療方法時，它們的價值尤其顯著。基因組編輯、幹細胞移植、病患來源組織模型、人類免疫系統重建、單細胞分析、空間生物學和人工智慧資料解讀等領域的持續創新，正在提升這些模型的預測效用，同時促進更符合倫理且更有效率的研究。生物醫學基礎設施、監管清晰度、研究經費、生物安全能力和轉化研究夥伴關係高度集中的地區發展勢頭最為強勁，而新興地區則透過定向投資和國際合作來提升自身能力。專注於檢驗模型設計、透明數據生成、動物福利和臨床相關終點的行業領導者，預計將在提高臨床前可靠性和加速治療創新方面擁有顯著優勢。未來人源化小鼠和大鼠模型研究的發展方向很可能是提高準確性、可重複性、負責任地整合人工智慧，以及加強臨床前證據與人類治療結果之間的一致性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：人源化小鼠與大鼠模型市場：依模型類型分類

  • 人源化大鼠模型
    • hACE2 大鼠模型
    • hCD4 大鼠模型
  • 免疫力缺乏模型
    • NOG模型
    • NSG模型
    • SCID模型
  • PDX 型號
    • 乳癌PDX
    • 結腸癌PDX
    • 肺癌PDX
  • 基因改造模型
    • 敲入式模型
    • 淘汰賽模特兒

第8章：人源化小鼠與大鼠模型市場：依人類細胞類型分類

  • CD34+幹細胞
  • PBMC
  • 患者來源的腫瘤組織（PDX）
  • 誘導性多能幹細胞衍生細胞

第9章：人源化小鼠與大鼠模型市場：依人源化技術分類

  • 基因人類化
    • 基因替換
    • 基因敲入
    • 基因編輯
  • 基於細胞的人源化
    • 周邊血單核細胞增殖
    • 組織移植
  • 人源化器官
  • 抗體平台的人源化

第10章：人源化小鼠與大鼠模型市場：依應用分類

  • 心血管系統
    • 動脈粥狀硬化模型
    • 高血壓模型
  • 免疫學
    • 自體免疫疾病模型
    • 發炎性疾病模型
  • 感染疾病
    • 細菌感染疾病模型
    • 病毒感染模型
  • 腫瘤學
  • 細胞療法測試

第11章：人源化小鼠與大鼠模型市場：依最終使用者分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司

第12章：人源化小鼠與大鼠模型市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：人源化小鼠與大鼠模型市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人源化小鼠與大鼠模型市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Axenis SAS
  • Biocytogen Pharmaceuticals Co Ltd
  • Champions Oncology Inc
  • Charles River Laboratories International Inc
  • Crown Bioscience Inc
  • Cyagen Biosciences Inc
  • Envigo RMS LLC
  • GemPharmatech Co Ltd
  • GenOway SA
  • Harbour BioMed
  • Hera BioLabs Inc
  • Ingenious Targeting Laboratory Inc
  • Inotiv Inc
  • Ozgene Pty Ltd
  • PhoenixBio Co Ltd
  • Taconic Biosciences Inc
  • The Jackson Laboratory
  • Trans Genic Inc
  • TransCure bioServices
Product Code: MRR-961BA04A2E3A

The Humanized Mouse & Rat Model Market is projected to grow by USD 494.48 million at a CAGR of 7.54% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 297.24 million
Estimated Year [2026] USD 317.57 million
Forecast Year [2032] USD 494.48 million
CAGR (%) 7.54%

Humanized Mouse & Rat Model Market Introduction

Humanized mouse and rat models are increasingly central to translational research because they enable in vivo investigation of human immune responses, disease biology, therapeutic mechanisms, and safety signals in a controlled preclinical setting. These models are created by introducing human cells, tissues, genes, microbiome components, or human-specific genetic sequences into immunodeficient or genetically engineered rodents, making them highly relevant for oncology, immunology, infectious disease, autoimmune disorders, regenerative medicine, drug metabolism, and pharmacokinetic studies. Demand is being shaped by the need to improve clinical translation, reduce late-stage attrition, and generate more predictive evidence before human trials. Scientific adoption is also supported by advances in CRISPR and other genome-editing technologies, stem cell biology, hematopoietic stem cell engraftment, patient-derived xenografts, human cytokine knock-in systems, and human immune system reconstitution. At the same time, ethical expectations around animal use are pushing researchers toward better-designed, higher-value studies aligned with the 3Rs principles: replacement, reduction, and refinement. The humanized mouse and rat model landscape is therefore evolving from a specialized research tool into a strategic platform for precision medicine, biologics development, vaccine evaluation, immune-oncology discovery, and human-relevant preclinical validation.

Transformative Shifts in the Humanized Rodent Model Landscape

The humanized rodent model landscape is undergoing a structural shift from conventional xenograft and knock-in systems toward highly customized, application-specific platforms that more closely represent human physiology. CRISPR-based gene editing has accelerated the development of models with targeted immune checkpoint pathways, cytokine networks, human leukocyte antigen expression, Fc receptor biology, and disease-specific genetic backgrounds. Immuno-oncology has been a major catalyst, with researchers using human immune system mice to evaluate checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates, cell therapies, tumor-infiltrating lymphocyte dynamics, and tumor microenvironment interactions. Infectious disease research has also intensified the use of humanized models for viral pathogenesis and vaccine response studies, particularly where species-specific host factors limit conventional animal testing. Another transformative shift is the rising use of patient-derived materials, including tumor tissue, immune cells, organoids, and stem cells, to support personalized therapeutic screening and mechanistic studies. Rat models are gaining attention where larger body size, repeated sampling, behavioral assessment, longitudinal pharmacology, and surgical feasibility offer advantages over mice. In parallel, regulatory and institutional review expectations are encouraging better model validation, reproducibility, transparent reporting, harmonized endpoints, and robust animal welfare oversight, making quality, traceability, and study design increasingly important differentiators.

Cumulative Impact of Artificial Intelligence on Humanized Models

Artificial intelligence is expanding the value of humanized mouse and rat models by improving model design, cohort selection, imaging analytics, biomarker interpretation, and translational prediction. AI-enabled literature mining and omics integration help researchers identify relevant human genes, immune pathways, disease signatures, candidate biomarkers, and model-selection criteria before development begins. Machine learning is being applied to histopathology, flow cytometry, single-cell sequencing, spatial biology, noninvasive imaging, and longitudinal behavioral data to detect complex patterns that may be missed by manual analysis. In drug discovery, AI can support dose selection, toxicity signal prioritization, response stratification, and cross-species extrapolation by integrating preclinical outputs with human clinical, molecular, and real-world biological datasets. This is particularly important in immuno-oncology, inflammatory disease, infectious disease, and advanced therapy development, where treatment response depends on dynamic immune cell interactions. AI also supports animal welfare and experimental efficiency by enabling refined endpoints, predictive monitoring, anomaly detection, and better statistical power planning, helping reduce unnecessary animal use while strengthening evidence quality. However, cumulative impact depends on validated datasets, standardized metadata, transparent algorithms, biological interpretability, and responsible governance. Humanized rodent models and AI are therefore converging into a more predictive preclinical ecosystem, but reproducibility and rigorous validation remain essential for adoption.

Key Regional Insights for Humanized Mouse & Rat Models

Asia-Pacific is becoming a high-priority region for humanized mouse and rat model research due to sustained biomedical investment, expanding contract research capabilities, and growing activity in oncology, vaccine development, regenerative medicine, infectious disease, and cell therapy. China, Japan, South Korea, India, Australia, and Singapore have strengthened life science infrastructure, genome-editing capabilities, biobanking, and translational research networks, supporting broader use of humanized immune system and patient-derived xenograft models. North America remains a leading center for advanced preclinical research, driven by deep academic infrastructure, a mature biotechnology ecosystem, established animal research governance, strong federal and institutional research support, and high demand for immuno-oncology, biologics, infectious disease, and rare disease models. Latin America is advancing gradually, with Brazil and Mexico supporting biomedical research capacity and increasing participation in translational studies, although infrastructure, funding continuity, biosafety readiness, and specialized model availability vary by institution. Europe continues to emphasize high-quality, ethically governed animal research, with strong adoption in immunology, oncology, infectious disease, pharmacology, and advanced therapy development; the region's strict animal welfare framework has encouraged validated, reproducible, and scientifically justified model use. The Middle East is building research capacity through investments in precision medicine, genomics, academic medical centers, and biomedical innovation hubs, particularly in countries prioritizing population genomics and translational healthcare. Africa's use of humanized mouse and rat models is more emerging but scientifically important, especially for infectious disease, immunology, vaccine research, and regionally relevant disease burdens; progress is tied to laboratory infrastructure, research partnerships, biosafety capacity, workforce training, and sustainable funding.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN is gaining relevance in the humanized mouse and rat model ecosystem as Singapore, Thailand, Malaysia, Vietnam, Indonesia, and the Philippines strengthen biomedical research, infectious disease surveillance, cancer research, vaccine science, and regional clinical translation capabilities. The group benefits from proximity to diverse disease burdens and growing laboratory networks, although specialized animal model capacity, advanced immunophenotyping, and high-containment infrastructure remain uneven across member states. The GCC is increasingly investing in biomedical infrastructure, genomics, academic hospitals, biobanking, and precision medicine initiatives, creating opportunities for translational research using humanized models in immunology, metabolic disease, oncology, inherited disorders, and population-specific therapeutic studies. The European Union plays a major role through harmonized research governance, strong animal welfare requirements, cross-border research funding, and extensive biomedical innovation networks, supporting validated and ethically refined humanized model applications across cancer, inflammation, infectious disease, toxicology, and advanced therapies. BRICS countries represent a diverse but influential group, with China and India expanding preclinical research capacity, Brazil and South Africa contributing to disease-relevant biomedical and vaccine research, and Russia maintaining scientific capabilities in immunology, pharmacology, virology, and experimental medicine. The G7 remains highly influential due to advanced research institutions, established regulatory science, strong biotechnology pipelines, mature animal care standards, and significant use of humanized rodent models in translational drug discovery. NATO member countries overlap with several advanced biomedical economies, where research security, bio-preparedness, vaccine development, infectious disease surveillance, and defense-related medical countermeasure studies contribute to sustained interest in humanized immune and infectious disease models.

Key Country Insights for Humanized Mouse & Rat Model Research

The United States is a global hub for humanized mouse and rat model research, supported by extensive academic laboratories, biotechnology innovation, immuno-oncology programs, cell and gene therapy development, infectious disease research, and established preclinical research infrastructure. Canada contributes through strong immunology, stem cell, oncology, vaccine, and infectious disease research, with emphasis on ethical animal care and translational collaboration. Mexico is expanding biomedical research capacity, particularly in oncology, metabolic disease, and infectious disease, while access to advanced humanized models is often linked to institutional partnerships and specialized research networks. Brazil is a key Latin American contributor, with established academic research in immunology, infectious disease, cancer biology, tropical medicine, and vaccine science. The United Kingdom has a prominent role in biomedical innovation, genetics, immunology, and preclinical pharmacology, supported by rigorous animal welfare governance and strong translational medicine programs. Germany is recognized for high-quality experimental medicine, immunology, oncology, biologics, and pharmacology research, with strong emphasis on reproducibility and regulatory alignment. France maintains robust activity in infectious disease, immunology, oncology, neuroscience, and vaccine research, while Italy and Spain contribute through academic medical research, cancer biology, neuroscience, inflammatory disease studies, and translational pharmacology. Russia has expertise in experimental pharmacology, virology, vaccine science, and immunology, though international collaboration dynamics and regulatory environments influence research access and integration. China has rapidly expanded capabilities in genome editing, oncology, infectious disease, stem cell science, biologics research, and contract research, making it a major user and developer of customized humanized models. India is strengthening translational research in oncology, infectious disease, vaccines, immunology, and biologics, supported by a growing biotechnology sector and clinical research base. Japan has advanced capabilities in regenerative medicine, immunology, oncology, aging-related disease research, and genetically engineered models, with strong scientific standards. Australia contributes through high-quality biomedical research, cancer immunology, infectious disease studies, public health research, and animal ethics governance. South Korea is increasingly important due to strong investment in biotechnology, cell therapy, biologics, oncology, precision medicine, and manufacturing-linked translational programs supported by advanced research infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize model selection based on biological relevance, endpoint validity, and translational fit rather than defaulting to familiar platforms. For immuno-oncology, human immune system composition, HLA compatibility, cytokine support, Fc receptor biology, tumor microenvironment representation, and graft-versus-host disease risk should guide study design. For infectious disease and vaccine studies, researchers should evaluate pathogen tropism, biosafety requirements, immune reconstitution quality, challenge model suitability, and clinically meaningful correlates of protection. Organizations should invest in standardized characterization, including flow cytometry, histopathology, cytokine profiling, genomic validation, human cell engraftment assessment, and longitudinal monitoring, to improve reproducibility across studies. Integrating AI-enabled analytics and multi-omics can strengthen biomarker discovery and response prediction, but outputs should be validated against transparent biological assumptions and independent datasets where possible. Strategic partnerships with specialized model developers, academic centers, biobanks, and translational laboratories can improve access to advanced models and disease-specific expertise. Leaders should also embed 3Rs principles into study planning by using power analysis, refined humane endpoints, noninvasive imaging, longitudinal sampling, and data-sharing practices that reduce redundant animal use. Finally, decision-makers should align humanized model evidence with regulatory expectations early in development, especially for biologics, cell therapies, gene therapies, vaccines, antibody-based therapies, and immune-modulating drugs.

Research Methodology

This executive summary is based on a structured secondary research approach using publicly available, verifiable sources such as peer-reviewed scientific literature, regulatory guidance, institutional animal welfare frameworks, biomedical research publications, clinical and translational science reports, and recognized public health and research policy resources. The analysis focuses on scientifically validated trends in humanized mouse and rat model development, including genome editing, immune system reconstitution, patient-derived xenograft modeling, infectious disease research, immuno-oncology applications, AI-enabled analytics, regenerative medicine, and regional research infrastructure. Insights were synthesized by comparing evidence across applications, geographies, research groups, and country-level innovation ecosystems while avoiding unverified numerical claims, market sizing, market share, and forecasting. Emphasis was placed on reproducibility, translational relevance, ethical governance, biosafety considerations, and the practical use of humanized rodent models in preclinical decision-making. The methodology also considers cross-disciplinary signals from immunology, oncology, pharmacology, toxicology, regenerative medicine, vaccine science, stem cell biology, and computational biology to provide an integrated view of the industry landscape.

Conclusion

Humanized mouse and rat models are becoming essential tools for bridging the gap between conventional preclinical testing and human clinical biology. Their value is strongest where human-specific immune mechanisms, pathogen interactions, tumor biology, genetic pathways, microbiome effects, or therapeutic modalities cannot be adequately studied in standard animal systems. Continued innovation in genome editing, stem cell engraftment, patient-derived tissue modeling, human immune system reconstitution, single-cell analytics, spatial biology, and AI-supported interpretation is improving the predictive utility of these models while supporting more ethical and efficient research. Regional momentum is strongest where biomedical infrastructure, regulatory clarity, research funding, biosafety capability, and translational partnerships converge, while emerging regions are building capacity through targeted investment and international collaboration. Industry leaders that focus on validated model design, transparent data generation, animal welfare, and clinically relevant endpoints will be better positioned to improve preclinical confidence and accelerate therapeutic innovation. The future of humanized mouse and rat model research will be defined by precision, reproducibility, responsible AI integration, and stronger alignment between preclinical evidence and human outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Humanized Mouse & Rat Model Market, by Model Type

  • 7.1. Introduction
  • 7.2. Humanized Rat Models
    • 7.2.1. hACE2 Rat Models
    • 7.2.2. hCD4 Rat Models
  • 7.3. Immunodeficient Models
    • 7.3.1. NOG Models
    • 7.3.2. NSG Models
    • 7.3.3. SCID Models
  • 7.4. PDX Models
    • 7.4.1. Breast Cancer PDX
    • 7.4.2. Colorectal Cancer PDX
    • 7.4.3. Lung Cancer PDX
  • 7.5. Transgenic Models
    • 7.5.1. Knock-In Models
    • 7.5.2. Knock-Out Models

8. Humanized Mouse & Rat Model Market, by Human Cell

  • 8.1. Introduction
  • 8.2. CD34+ Stem Cells
  • 8.3. PBMC
  • 8.4. Patient Tumor Tissue (PDX)
  • 8.5. iPSC-derived Cells

9. Humanized Mouse & Rat Model Market, by Humanization Technology

  • 9.1. Introduction
  • 9.2. Genetic Humanization
    • 9.2.1. Gene Replacement
    • 9.2.2. Gene Knock-In
    • 9.2.3. Gene Editing
  • 9.3. Cell-Based Humanization
    • 9.3.1. PBMC Engraftment
    • 9.3.2. Tissue Engraftment
  • 9.4. Organ Humanization
  • 9.5. Antibody Platform Humanization

10. Humanized Mouse & Rat Model Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular
    • 10.2.1. Atherosclerosis Models
    • 10.2.2. Hypertension Models
  • 10.3. Immunology
    • 10.3.1. Autoimmune Disorder Models
    • 10.3.2. Inflammatory Disease Models
  • 10.4. Infectious Disease
    • 10.4.1. Bacterial Infection Models
    • 10.4.2. Viral Infection Models
  • 10.5. Oncology
  • 10.6. Cell Therapy Testing

11. Humanized Mouse & Rat Model Market, by End User

  • 11.1. Introduction
  • 11.2. Academic Research Institutes
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Biotech Companies

12. Humanized Mouse & Rat Model Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Humanized Mouse & Rat Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Humanized Mouse & Rat Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Axenis SAS
  • 16.2. Biocytogen Pharmaceuticals Co Ltd
  • 16.3. Champions Oncology Inc
  • 16.4. Charles River Laboratories International Inc
  • 16.5. Crown Bioscience Inc
  • 16.6. Cyagen Biosciences Inc
  • 16.7. Envigo RMS LLC
  • 16.8. GemPharmatech Co Ltd
  • 16.9. GenOway SA
  • 16.10. Harbour BioMed
  • 16.11. Hera BioLabs Inc
  • 16.12. Ingenious Targeting Laboratory Inc
  • 16.13. Inotiv Inc
  • 16.14. Ozgene Pty Ltd
  • 16.15. PhoenixBio Co Ltd
  • 16.16. Taconic Biosciences Inc
  • 16.17. The Jackson Laboratory
  • 16.18. Trans Genic Inc
  • 16.19. TransCure bioServices

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMANIZED RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMANIZED RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HACE2 RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HACE2 RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HACE2 RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HCD4 RAT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HCD4 RAT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HCD4 RAT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNODEFICIENT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNODEFICIENT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNODEFICIENT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NOG MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NOG MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NOG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NSG MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NSG MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NSG MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SCID MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SCID MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SCID MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PDX MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PDX MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PDX MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER PDX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER PDX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER PDX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER PDX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER PDX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER PDX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER PDX MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER PDX MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER PDX MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSGENIC MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL KNOCK-IN MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL KNOCK-OUT MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL KNOCK-OUT MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL KNOCK-OUT MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CD34+ STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CD34+ STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CD34+ STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PBMC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PBMC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PBMC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT TUMOR TISSUE (PDX) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT TUMOR TISSUE (PDX) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT TUMOR TISSUE (PDX) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IPSC-DERIVED CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IPSC-DERIVED CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IPSC-DERIVED CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENETIC HUMANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENETIC HUMANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENETIC HUMANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE REPLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENE REPLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE REPLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENE KNOCK-IN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE KNOCK-IN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENE KNOCK-IN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CELL-BASED HUMANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL-BASED HUMANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CELL-BASED HUMANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PBMC ENGRAFTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PBMC ENGRAFTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PBMC ENGRAFTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TISSUE ENGRAFTMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TISSUE ENGRAFTMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TISSUE ENGRAFTMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORGAN HUMANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ORGAN HUMANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORGAN HUMANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIBODY PLATFORM HUMANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIBODY PLATFORM HUMANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIBODY PLATFORM HUMANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ATHEROSCLEROSIS MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ATHEROSCLEROSIS MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ATHEROSCLEROSIS MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HYPERTENSION MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HYPERTENSION MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HYPERTENSION MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL AUTOIMMUNE DISORDER MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOIMMUNE DISORDER MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL AUTOIMMUNE DISORDER MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLAMMATORY DISEASE MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFLAMMATORY DISEASE MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLAMMATORY DISEASE MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIAL INFECTION MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIAL INFECTION MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIAL INFECTION MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VIRAL INFECTION MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VIRAL INFECTION MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VIRAL INFECTION MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 245. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 247. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 290. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 291. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 292. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 293. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 295. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 297. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 299. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 304. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 305. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 306. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 307. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 308. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 309. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 310. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 312. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CELL-BASED HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMAN CELL, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZATION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GENETIC HUMANIZATION, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY